Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Slightly undervalued vs peers
Very low or no dividends
Weak margins and returns
Risk / Profitability
Risk: High
Profitability: Average
About
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog...
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Slightly undervalued vs peers
Very low or no dividends
Weak margins and returns
$ 1.21
About
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog...
